{"id":32841,"date":"2014-10-06T08:49:01","date_gmt":"2014-10-06T12:49:01","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=32841"},"modified":"2014-10-07T04:10:52","modified_gmt":"2014-10-07T08:10:52","slug":"horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841","title":{"rendered":"Horizon Pharma PLC (NASDAQ:HZNP) Gets Orphan-Drug Designation for ACTIMMUNE(R)"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 10\/06\/2014 (wallstreetpr) \u2013\u00a0According to reports, US Food and Drug Administration has granted <strong>Horizon Pharma PLC (NASDAQ:HZNP)<\/strong> the orphan-drug designation for ACTIMMUNE(R). HZNP is a well know biopharmaceutical company and offers various products for inflammation, arthritis and orphan diseases. ACTIMMUNE(R) is an interferon gamma-1b drug which is used for the treatment of Friedreich&#8217;s ataxia (FA). As per the information, it is one of the rarest diseases in the world for which there is no officially approved treatment available.<\/p>\n<p style=\"text-align: justify;\"><strong>Insights of the matter: <\/strong><\/p>\n<p style=\"text-align: justify;\">The U.S. Orphan Drug Act (ODA) is known for providing special status to all those drugs, or biological products to treat a rare condition or disease that affects not more than 2,00000 patients in United States. The best advantage one can get from ODA is that Orphan designation qualifies the sponsor of the medicine or drug for a lot of incentives; both financial and developmental incentives. These incentives mainly include tax advantages and credits for qualified clinical testing.<\/p>\n<p style=\"text-align: justify;\">A marketing drug application prepared for the prescription of a drug that has got orphan-drug designation recently is not subjected to the fees charged for Prescription Drug User Fee Act (PDUFA). The orphan designation can also provide ACTIMMUNE on one condition, and that is if it is approved for the treatment of FA. The minimum timeline associated towards it is seven years exclusively for this indication.<\/p>\n<p style=\"text-align: justify;\">FA is one of the rarest, life-shortening, debilitating and degenerative neuro-muscular disorder. According to a survey, it affects to one out of every 50,000 people in US. There is no age bracket for this health issue, which means that anyone right from a five-year-old child to any adult can be affected by FA.\u00a0 An inclining loss of muscle power and coordination can often lead to a motor incapacitation or use of wheelchair full-time. Most of the youngsters affected by FA need walker, cane or wheelchair.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 10\/06\/2014 (wallstreetpr) \u2013\u00a0According to reports, US Food and Drug Administration has granted Horizon Pharma PLC (NASDAQ:HZNP) the orphan-drug designation for ACTIMMUNE(R). HZNP is [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":32842,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[2236],"tags":[10160,4907,10161],"stock_ticker":[],"class_list":["post-32841","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","tag-horizon-pharma-plc-nasdaqhznp","tag-nasdaqhznp","tag-the-u-s-orphan-drug-act","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Horizon Pharma PLC (NASDAQ:HZNP) Gets Orphan-Drug Designation for ACTIMMUNE(R) - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Horizon Pharma PLC (NASDAQ:HZNP) Gets Orphan-Drug Designation for ACTIMMUNE(R) - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 10\/06\/2014 (wallstreetpr) \u2013\u00a0According to reports, US Food and Drug Administration has granted Horizon Pharma PLC (NASDAQ:HZNP) the orphan-drug designation for ACTIMMUNE(R). HZNP is [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-10-06T12:49:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2014-10-07T08:10:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Horizon-Pharma-Inc.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"198\" \/>\n\t<meta property=\"og:image:height\" content=\"254\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Donna Fago\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Donna Fago\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841\"},\"author\":{\"name\":\"Donna Fago\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\"},\"headline\":\"Horizon Pharma PLC (NASDAQ:HZNP) Gets Orphan-Drug Designation for ACTIMMUNE(R)\",\"datePublished\":\"2014-10-06T12:49:01+00:00\",\"dateModified\":\"2014-10-07T08:10:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841\"},\"wordCount\":325,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Horizon-Pharma-Inc.jpg\",\"keywords\":[\"Horizon Pharma PLC (NASDAQ:HZNP)\",\"NASDAQ:HZNP\",\"The U.S. Orphan Drug Act\"],\"articleSection\":[\"Business\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841\",\"name\":\"Horizon Pharma PLC (NASDAQ:HZNP) Gets Orphan-Drug Designation for ACTIMMUNE(R) - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Horizon-Pharma-Inc.jpg\",\"datePublished\":\"2014-10-06T12:49:01+00:00\",\"dateModified\":\"2014-10-07T08:10:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Horizon-Pharma-Inc.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Horizon-Pharma-Inc.jpg\",\"width\":198,\"height\":254},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Horizon Pharma PLC (NASDAQ:HZNP) Gets Orphan-Drug Designation for ACTIMMUNE(R)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\",\"name\":\"Donna Fago\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"caption\":\"Donna Fago\"},\"description\":\"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.\",\"sameAs\":[\"http:\/\/www.WallStreetPR.com\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Horizon Pharma PLC (NASDAQ:HZNP) Gets Orphan-Drug Designation for ACTIMMUNE(R) - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841","og_locale":"en_US","og_type":"article","og_title":"Horizon Pharma PLC (NASDAQ:HZNP) Gets Orphan-Drug Designation for ACTIMMUNE(R) - Wall Street PR","og_description":"Boston, MA 10\/06\/2014 (wallstreetpr) \u2013\u00a0According to reports, US Food and Drug Administration has granted Horizon Pharma PLC (NASDAQ:HZNP) the orphan-drug designation for ACTIMMUNE(R). HZNP is [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-10-06T12:49:01+00:00","article_modified_time":"2014-10-07T08:10:52+00:00","og_image":[{"width":198,"height":254,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Horizon-Pharma-Inc.jpg","type":"image\/jpeg"}],"author":"Donna Fago","twitter_misc":{"Written by":"Donna Fago","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841"},"author":{"name":"Donna Fago","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84"},"headline":"Horizon Pharma PLC (NASDAQ:HZNP) Gets Orphan-Drug Designation for ACTIMMUNE(R)","datePublished":"2014-10-06T12:49:01+00:00","dateModified":"2014-10-07T08:10:52+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841"},"wordCount":325,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Horizon-Pharma-Inc.jpg","keywords":["Horizon Pharma PLC (NASDAQ:HZNP)","NASDAQ:HZNP","The U.S. Orphan Drug Act"],"articleSection":["Business"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841","url":"https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841","name":"Horizon Pharma PLC (NASDAQ:HZNP) Gets Orphan-Drug Designation for ACTIMMUNE(R) - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Horizon-Pharma-Inc.jpg","datePublished":"2014-10-06T12:49:01+00:00","dateModified":"2014-10-07T08:10:52+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Horizon-Pharma-Inc.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Horizon-Pharma-Inc.jpg","width":198,"height":254},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/horizon-pharma-plc-nasdaqhznp-gets-orphan-drug-designation-for-actimmuner-32841#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Horizon Pharma PLC (NASDAQ:HZNP) Gets Orphan-Drug Designation for ACTIMMUNE(R)"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84","name":"Donna Fago","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","caption":"Donna Fago"},"description":"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.","sameAs":["http:\/\/www.WallStreetPR.com"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/32841","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=32841"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/32841\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/32842"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=32841"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=32841"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=32841"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=32841"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}